SCLX Stock Analysis: Buy, Sell, or Hold?
SCLX - Scilex Holding Company Common Stock
$6.95
0.01 (0.14%)
▲
5d:
+4.28%
30d:
-24.46%
90d:
-13.56%
HOLD
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 12, 2026
2d
Get Alerted When SCLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SCLX trades at premium valuation expecting 9.6% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: SCLX trades at premium valuation expecting 9.6% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.36
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.57
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SCLX is currently trading at $6.95, which is considered slightly low relative to its 30-day fair value range of $6.69 to $8.87. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.5) compared to its historical average (7.2). At these levels, the market is pricing in 9.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SCLX is showing sideways momentum. Immediate support is located at $6.25, while resistance sits at $7.26.
Market Sentiment: SCLX scores 87/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $490.00 (+6950.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SCLX is showing sideways momentum. Immediate support is located at $6.25, while resistance sits at $7.26.
Market Sentiment: SCLX scores 87/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $490.00 (+6950.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$6.69 -
$8.87
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (87/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 6950.4% below Wall St target ($490.00)
- NEUTRAL: Trading at premium valuation - market expects 9.6% growth which is achievable
- CAUTION: Bottoming setup, but lagging the sector by 22% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$6.69 -
$8.87
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$6.25
Resistance Level
$7.26
Current Trend
Sideways
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.52
Wall Street Target
$490.00
(+6950.4%)
Revenue Growth (YoY)
72.1%
Valuation Premium vs History
+9.6% premium
PE vs Historical
9.5 vs 7.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.6%
(market-implied from PE analysis)
1-Year Target
$7.62
(+10%)
2-Year Target
$8.35
(+20%)
3-Year Target
$9.15
(+32%)
3-Yr Target (if PE normalizes)
(PE: 10→7)
PE COMPRESSION
$6.92
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 09, 2026 2:45 AM ET
Data refreshes hourly during market hours. Next update: 3:45 AM
Data refreshes hourly during market hours. Next update: 3:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1277 | 49 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 53 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$270 | 53 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$234 | 53 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$135 | 51 HOLD |
